Stock Analysis

Little Excitement Around Kanoria Chemicals & Industries Limited's (NSE:KANORICHEM) Revenues As Shares Take 27% Pounding

Unfortunately for some shareholders, the Kanoria Chemicals & Industries Limited (NSE:KANORICHEM) share price has dived 27% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 38% in that time.

Following the heavy fall in price, Kanoria Chemicals & Industries' price-to-sales (or "P/S") ratio of 0.2x might make it look like a buy right now compared to the Chemicals industry in India, where around half of the companies have P/S ratios above 1.4x and even P/S above 4x are quite common. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

See our latest analysis for Kanoria Chemicals & Industries

ps-multiple-vs-industry
NSEI:KANORICHEM Price to Sales Ratio vs Industry March 1st 2025
Advertisement

How Kanoria Chemicals & Industries Has Been Performing

For instance, Kanoria Chemicals & Industries' receding revenue in recent times would have to be some food for thought. It might be that many expect the disappointing revenue performance to continue or accelerate, which has repressed the P/S. However, if this doesn't eventuate then existing shareholders may be feeling optimistic about the future direction of the share price.

Although there are no analyst estimates available for Kanoria Chemicals & Industries, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.

What Are Revenue Growth Metrics Telling Us About The Low P/S?

There's an inherent assumption that a company should underperform the industry for P/S ratios like Kanoria Chemicals & Industries' to be considered reasonable.

In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 5.9%. This has soured the latest three-year period, which nevertheless managed to deliver a decent 6.4% overall rise in revenue. Although it's been a bumpy ride, it's still fair to say the revenue growth recently has been mostly respectable for the company.

Comparing the recent medium-term revenue trends against the industry's one-year growth forecast of 14% shows it's noticeably less attractive.

With this in consideration, it's easy to understand why Kanoria Chemicals & Industries' P/S falls short of the mark set by its industry peers. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.

The Key Takeaway

Kanoria Chemicals & Industries' P/S has taken a dip along with its share price. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

Our examination of Kanoria Chemicals & Industries confirms that the company's revenue trends over the past three-year years are a key factor in its low price-to-sales ratio, as we suspected, given they fall short of current industry expectations. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. If recent medium-term revenue trends continue, it's hard to see the share price experience a reversal of fortunes anytime soon.

Before you settle on your opinion, we've discovered 3 warning signs for Kanoria Chemicals & Industries (1 is concerning!) that you should be aware of.

If you're unsure about the strength of Kanoria Chemicals & Industries' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Valuation is complex, but we're here to simplify it.

Discover if Kanoria Chemicals & Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:KANORICHEM

Kanoria Chemicals & Industries

Manufactures and sells Industrial Chemicals in India.

Low risk and slightly overvalued.

Advertisement

Weekly Picks

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8227.1% undervalued
28 users have followed this narrative
4 users have commented on this narrative
22 users have liked this narrative
WO
BMBL logo
woodworthfund on Bumble ·

Swiped Left by Wall Street: The BMBL Rebound Trade

Fair Value:US$960.0% undervalued
10 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
WE
WealthAP
DUOL logo
WealthAP on Duolingo ·

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Fair Value:US$268.6433.4% undervalued
26 users have followed this narrative
4 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

DE
HIMS logo
Deep_Insights on Hims & Hers Health ·

Hims & Hers Health aims for three dimensional revenue expansion

Fair Value:US$173.0279.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IN
EDV logo
InvestorNTrader on Endeavour Group ·

Endeavour Group's Future PE Expected to Climb to 15.51%

Fair Value:AU$2.8628.7% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BA
NVO logo
bactrian on Novo Nordisk ·

A Quality Compounder Marked Down on Overblown Fears

Fair Value:US$9540.8% undervalued
97 users have followed this narrative
8 users have commented on this narrative
1 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
69 users have followed this narrative
12 users have commented on this narrative
21 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25429.4% overvalued
72 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0226.0% undervalued
1024 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative